Glenmark shares jump after subsidiary inks pact with China's Hansoh Pharma for cancer drugGlenmark shares jump after subsidiary inks pact with China's Hansoh Pharma for cancer drug

Introduction

Leading pharmaceutical firm secures exclusive rights to Aumolertinib from Hansoh Pharma for NSCLC treatment. The agreement covers multiple regions, including Middle East, Africa, South Asia, Australia, New Zealand, and select global markets.

Also Read: Oberoi Group company EIH LTD signs luxury resort deal at Makaibari Tea Estate in Darjeeling

Share price movement of Glenmark Pharmaceuticals

On December 17, 2025, Glenmark Pharmaceuticals Ltd opened at ₹1,971.05, up 0.26% from its previous close of ₹1,966.05. The stock reached a high of ₹1,975.00 (0.46%) and a low of ₹1,946.00 (-1.02%). By 11:44 AM, it traded at ₹1,953.90, down 0.62%, with a market cap of ₹55,139.22 crore.

Glenmark Secures Rights to Aumolertinib

Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals, has secured exclusive rights to develop and commercialize Aumolertinib from Hansoh Pharma across multiple regions including Middle East, Africa, and South Asia.

The agreement covers Australia, New Zealand, Russia/CIS, and select Caribbean countries. Glenmark will pay an upfront low double-digit million USD, with potential milestones exceeding US$1 billion plus tiered royalties on net sales.

Aumolertinib is approved by the UK MHRA and China NMPA for multiple NSCLC indications. It treats EGFR-mutated locally advanced or metastatic non-small cell lung cancer and T790M mutation-positive NSCLC.

Stock performance of Glenmark Pharmaceuticals for Period of 1 week, 6 months, and 1 year

Glenmark Pharmaceuticals Ltd delivered a 0.80% return over the past week. It gained 20.2% in the past six months and 29.9% over the past year.

Also Read: SBI launches YONO 2.0 to double app user to 20 Cr over the next 2 years

Shareholding pattern of Glenmark Pharmaceuticals

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	46.70%	46.70%	46.70%
FII	20.70%	20.60%	23.20%
DII	18.70%	17.70%	14.60%
Public	14.00%	15.10%	15.60%

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK) is a research-led global pharmaceutical company operating in Branded, Generics, and OTC segments, with focus on respiratory, dermatology, oncology, 11 manufacturing facilities, and presence in over 80 countries.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs